THE USE OF SIMVASTATIN, AN HMG COA REDUCTASE INHIBITOR, IN OLDER PATIENTS WITH HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS

Epidemiological evidence suggests that elevated serum cholesterol, especially the low density lipoprotein (LDL) fraction, the total/high density lipoprotein (HDL)–cholesterol ratio, and the LDL/HDL–cholesterol ratio, remains a risk factor for atheromatous disease up to the age of 79 years. We studied the efficacy and tolerability of simvastatin, an HMG CoA reductase inhibitor, in 20 patients aged 65 to 75 years with clinical evidence of atheromatous disease. After four weeks of treatment, there was a 29% fall in LDL‐cholesterol levels (P < .01 vs placebo) with low dose simvastatin and a 38% fall with high dose simvastatin (P < .001 vs placebo). Similar falls were seen in total cholesterol levels and the LDL/HDL–cholesterol and total/HDL–cholesterol ratios. Apoprotein B levels decreased by approximately 20% with both doses (P < .05 vs placebo). In an open extension of the study, the decreases in lipid parameters were sustained for a further 48 weeks of treatment with doses of simvastatin ranging from 10 to 40 mg. Two patients required the addition of cholestyramine. Although a small study like this cannot establish safety and tolerance, side effects were minor and did not require stopping therapy in any patient. Simvastatin is an effective cholesterol lowering agent in older patients. © 1990 The American Geriatrics Society